The correction is one of the largest in Abbott's recent continuous glucose monitor business, which dominates the global ...

Last year, Abbott issued a similar correction for a small number of FreeStyle Libre 3 sensors in the United States that could ...

Abbot has issued a medical device correction for some of its glucose sensor products after identifying a manufacturing issue that can lead to falsely low glucose readings. The correction affects about ...

Abbott issued a medical device correction for some of its glucose sensors after internal testing found that some sensors may ...

Big strategic acquisitions typically precede a return of venture capital to younger companies — a "flywheel" effect that ...

We recently published 10 Stocks Jim Cramer Talked About. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer ...

Abbott is moving to acquire Exact Sciences, a molecular diagnostics company that specializes in the detection of early-stage ...

By bringing Exact Sciences into the fold, the expectation is that the focus on cancer diagnostics can provide a jolt to the ...

Cancerguard, a multi-cancer early detection blood test.

Global healthcare leader Abbott announced Thursday that it has reached a $23 billion deal to acquire Exact Sciences.

Abbott Laboratories could be looking to acquire Exact Sciences, according to a report from Bloomberg, citing people close to ...

These healthcare stocks have long-term and profitable growth runways.